Hospital Valle Hebron/Institut de Recerca Vall de hebron
Contacto
correo-e:joan.sayos@vhir.org
---
El Grupo de Inmunobiología del Institut de Recerca Vall d'Hebron de
Barcelona busca candidatos para solicitar un CONTRATO POST-DOCTORAL de 3
años de duración con cargo al subprograma Juan de la Cierva del MICINN
(MICINN-JDC).
http://www.idi.mineco.gob.es/portal/site/MICINN/
El candidato se incorporará a nuestro Grupo para trabajar en un proyecto
financiado por el FIS :“CD300 immunoreceptors; Functional
characterization and implication in inflammatory demyelinating
diseases.”
Perfil del candidato:
- Doctor en Bioquímica, Biologia, Medicina o similar.
- Un mínimo de tres publicacions del primer quartil (ISI)
- Dedicación a tiempos completo.
- Se valorará experiencia en Neurociencias, Inmunologia i/o en modelos animales
(ratones o rata)
Las personas interesades enviar CV a:
Dr. Joan Sayós (
joan.sayos@vhir.org)
Tel: 93 4893000 ext 3753
Información complementaria de la oferta:
Información sobre el proyecto de Investigación
The CD300family of immunoreceptors is composed by six members,
CD300a/IRP60, CD300b/IREM3, CD300c/CMRF35, CD300d, CD300e/IREM2 and
CD300f/IREM1. All of them share an extracellular region comprising a
single Ig-like domain and, with the exception of CD300a, a myeloid
linage restricted pattern of expression. In addition to the expression
on myeloid cells, CD300a is found in some subsets of T, B and NK cells.
The Immunobiology group is focused on the study of the structure and
function of the CD300 family of immune receptors, as well as in their
involvement in different human pathologies.
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the
central nervous system (SNS) that affects more than 2.5 million
individuals worldwide. The first symptoms appear between 20 and 30 years
and is the main neurological disease in young adults, with higher
incidence in women. Although the mechanisms underlying MS pathogenesis
are still unclear, it is well known that patients' blood-brain barrier
allows the passage of macrophages and lymphocytes to the NHS thereby
initiating an inflammatory process. This inflammatory response includes
activation of microglial cells and autoimmune attack against white
matter oligodendrocytes. We propose, based on previous experimental
data, the study of the role of the CD300f in the pathophysiology of this
disease. First, we are working in the identification of the
physiological ligand for this receptor, that we know is expressed by
certain cells in the SNS. Secondly, the analysis of the role of soluble
forms of CD300f in the
development of the disease by studying their expression in fluid
samples of multiple sclerosis patients. Since activation of microglia
and macrophages is critical in the development and expansion of MS
lesions, the study of the mechanisms that regulate the activation of
these cells may be of vital importance in the development of new
therapeutic agents for the treatment of this disease.
Publicaciones recientes del Grupo de Investigación sobre el tema
Comas-Casellas E, Martínez-Barriocanal A, Ejarque-Ortiz, A, Miro, F,
Schwartz S Jr, Martín M, and Sayós J. CD300d is a new member of the
CD300 family of receptors that regulates their surface expression. J
Biol Chem. 287: 9682-9693. (2012)
Peluffo, H, Alí-Ruiz, D, Ejarque-Ortíz, A, Heras-Alvarez, V,
Comas-Casellas, E, Martínez-Barriocanal, A, Kamaid, A, Alvarez-Errico,
D, Negro, ML, Lago, N, Schwartz Jr, S, Villaverde, A and Sayós, J.
Overexpression of the immunoreceptor CD300f has a neuroprotective role
in a model of acute brain injury. Brain Pathol. 22:318-328. (2012)
Martínez-Barriocanal A, Comas-Casellas E, Schwartz S Jr, Martín M, and
Sayós J. CD300 heterocomplexes, a new and family-restricted mechanism
for myeloid cell signaling regulation. J. Biol. Chem. 285:41781-94.
(2010).
